ScinoPharm to provide topiramate API for Vivus anti-obesity drug

The FDA-approved Qsymia is used as a treatment for chronic weight management in adults who are obese or overweight with a weight-related comorbidity.

Clinical studies have showed that Qsymia can effectively assist in weight management.

In addition to chronic weight management, Qsymia, which comprises of topiramate, an anticonvulsant and phentermine, an appetite suppressant, is used for the treatment of epilepsy and other nervous system disorders.

ScinoPharm president and CEO Jo Shen said the company’s partnership with Vivus began with the supply of topiramate for the Qsymia clinical development program.

"We are committed to providing VIVUS and our other customers with high quality APIs, ensuring fast time-to-market," Shen added.